title: Respiratory response to salbutamol (albuterol) in ventilator-dependent infants with chronic lung disease: pressurized aerosol delivery versus intravenous injection.
abstract: OBJECTIVE
  To compare the effects of intravenously injected with inhaled salbutamol in ventilator dependent infants with chronic lung disease (CLD).
  
  
  METHODS
  Prospective randomized study which each patient served as his/her own control.
  
  
  METHODS
  Multidisciplinary neonatal and pediatric ICU.
  
  
  METHODS
  8 ventilator dependent premature infants with CLD.
  
  
  METHODS
  Salbutamol, 10 micrograms/kg was given intravenously, and 10-19 h later, twice 100 micrograms as pressurized aerosol, or vice versa, sequence randomized. The pressurized aerosol was delivered by a metered dose inhaler into a newly developed aerosol holding chamber, integrated into the inspiratory limb of the patient circuit. Respiratory system mechanics were assessed by the single breath occlusion method before and 10 and 60 min after drug administration.
  
  
  RESULTS
  Compliance improved significantly after intravenous injection (0.48 +/- 0.18 to 0.67 +/- 0.16, p < 0.01 and 0.59 +/- 0.23 ml/cmH2O/kg, NS, (mean +/- 1 SD) and after inhalation (0.46 +/- 0.19 to 0.64 +/- 0.32, p < 0.01 and 0.56 +/- 0.31 ml/cmH2O/kg, NS). Resistance decreased after iv. use (0.38 +/- 0.17 to 0.25 +/- 0.11, p < 0.001 and 0.25 +/- 0.10 cmH2O/ml/s, NS) and after inhalation (0.35 +/- 0.12 to 0.27 +/- 0.09, p < 0.01 and 0.28 +/- 0.12 cmH2O/ml/s, NS). Heart rate increased significantly after both routes of application, whereas mean arterial pressure, respirator settings, FIO2, transcutaneous SO2 and capillary PCO2 did not change.
  
  
  CONCLUSIONS
  Inhaled and intravenous salbutamol improves pulmonary mechanics to the same extent with comparable side effects, and may therefore be used to facilitate weaning from respirators.
authors.affiliation: PICU/NICU, University Children's Hospital, Inselspital, Bern, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Pfenninger
authors.forename: C
authors.initials: C
authors.lastname: Aebi
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000420:Albuterol / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D001784:Blood Gas Analysis; D001785:Blood Gas Monitoring, Transcutaneous; D001794:Blood Pressure / Q000187:drug effects; D001997:Bronchopulmonary Dysplasia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D002908:Chronic Disease; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007275:Injections, Intravenous; D007363:Intensive Care Units, Neonatal; D008171:Lung Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D011446:Prospective Studies; D012121:Respiration, Artificial; D015656:Respiratory Mechanics / Q000187:drug effects*; D015300:Ventilator Weaning
chemical_list: D000336:Aerosols; D000420:Albuterol